Sandbox Reserved 1660
From Proteopedia
This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
Structure of mouse CD1d
CD1 (Cluster of Differentiation 1) is a family of glycoproteins involved in the presentation of antigens on the surface of specific cells to NKT cells. Amongst these CD1-presenting cells can be counted splenic dendritic cells, marginal zone B cells and CD4+CD8+ thymocytes. This family is made of two main groups: group 1 is composed of CD1a, b and c proteins and group 2 is composed of CD1d proteins[1].
FunctionRole in the immune systemCD1d protein is a molecule of the immune system. It is involved in presenting a lipid antigen to NKT cells. Indeed, these proteins are located on the surface of the plasma membrane of APC cells. When the recognition between the CD1d bound to its lipid ligand and the TCR of a NKT cell occurs, the lymphocyte turns out to be activated. Thus, the production of cytotoxic molecules such as Th1, Th2, interleukin-4 and INF-gamma is triggered by this activation[2][3]. Therefore, CD1d proteins are precursors of the adaptive immune reaction which are key activators of the NKT cells. As a result, a deficiency of CD1d proteins may lead to a deficiency of the NKT cells functioning and thus to autoimmune diseases and cancers.
Ligands presented by CD1dThe ligands that can be presented by CD1d to NKT or other CD1d-restricted T cells are very specific. Only a narrow set of molecules can bind its recognition site. Thus, it limits the risk of other similar molecules or binding CD1d proteins and ensures that the immune response is accurate. Among these molecules are included glycolipids from a marine sponge, bacterial glycolipids, normal endogenous glycolipids, tumor-derived phospholipids and glycolipids, and nonlipidic molecules[4].
Structure
CD1d protein is made of 2 chains[5]:
Additionally, there are two bound to the alpha chain via N-glycosylations and three types of small molecules bound to that protein[5]. CD1d molecules are structurally similar to Major Histocompatibility Complex Class I, but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This is located at the A and F pockets in the region of the alpha helices[6]. Impact of ligand-bindingConformational variationNTK cells are a subset of T cells (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the cytokine release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR[3][6]. between CD1d no ligand and structure of bovine CD1d with bound C12-di-sulfatide. CD1d affinityCD1d proteins lipid recognition is based on the interaction of the protein with its ligand. Nevertheless, the recognition relies on two recognitions. The first one is the recognition of the head of the lipid and the second one is the recognition of the length of the molecule. Because there are more than one condition to fill in order to interact with CD1d proteins, the affinity for a lipid depends itself on a plurality of parameters which modulates it[3][6][7]. ApplicationsImmunotherapeutic toolThe presentation of many of ligands can have immunopotentiating effects, such as serving as an adjuvant against malaria or resulting in a more rapid clearance of certain virus infections. They can also be protective in autoimmune diseases or cancer[3][4][8]. The presence of high amount of CD1d proteins on the cell surface of NKT cells gives rise to a novel type of NKT cells. This larger amount of CD1d proteins allows the Cd1d high NKT cells to bind more alpha-galactosylceramide molecules and therefore to can produce greater levels of interleukin-4 and INF-gamma molecules leading to possible therapeutical effects[3]. NKT cells markerCD1 molecules can also be used as NKT cell markers. Indeed, a CD1 molecule can be engineered to become fluorescent by binding a fluorescent-potent molecule to it. When the engineered complex interacts with a NKT cell, the fluorescent signal is emitted and therefore the NKT cells can be spotted[9]. See AlsoReferences
|